See the DrugPatentWatch profile for ezetimibe
The cost of ezetimibe can vary significantly depending on factors such as dosage, quantity, pharmacy, and insurance coverage. Without insurance, a 30-day supply of generic ezetimibe (typically 10 mg tablets) can range from approximately $20 to over $100 [1].
How much does ezetimibe cost with insurance?
When covered by insurance, out-of-pocket costs for ezetimibe are generally lower. Co-pays can range from a few dollars to $20 or more per prescription, depending on the specific insurance plan [1]. Many insurance plans cover generic ezetimibe, which is a more affordable option.
Can I get ezetimibe cheaper without insurance?
Yes, prices can be reduced by using discount cards or coupons, or by purchasing from online pharmacies that may offer lower prices than traditional brick-and-mortar stores. Comparing prices across different pharmacies is also a strategy to find more affordable options [1].
When does the ezetimibe patent expire?
The patents for ezetimibe have largely expired, which has allowed for the availability of generic versions of the drug. For example, patents related to the drug's composition of matter and method of use have seen their exclusivity periods end, opening the door for generic competition [2]. DrugPatentWatch.com tracks patent expiries for numerous drugs, including ezetimibe [2].
What are the common dosages for ezetimibe?
Ezetimibe is typically prescribed in a 10 mg tablet, taken once daily [3]. It can be used alone or in combination with other cholesterol-lowering medications, such as statins.
How does ezetimibe work to lower cholesterol?
Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine. It targets a specific protein, Niemann-Pick C1-Like 1 (NPC1L1), located on the brush border of enterocytes, thereby reducing the amount of dietary and biliary cholesterol that reaches the liver [4]. This leads to a decrease in LDL cholesterol levels.
What are the side effects of ezetimibe?
Common side effects associated with ezetimibe include diarrhea, fatigue, stomach pain, and muscle aches [3]. Less common but more serious side effects can include liver problems and allergic reactions. Patients are advised to discuss any concerns with their healthcare provider.
Are there alternatives to ezetimibe for lowering cholesterol?
Yes, several alternatives exist for lowering cholesterol. These include lifestyle modifications such as diet and exercise, as well as other classes of cholesterol-lowering medications, notably statins (e.g., atorvastatin, simvastatin), PCSK9 inhibitors, bile acid sequestrants, and fibrates. The choice of treatment depends on individual patient needs, cholesterol levels, and tolerance for specific medications [4].
Who manufactures ezetimibe?
The original brand-name drug, Zetia, was developed by Merck & Co. Following patent expiries, numerous pharmaceutical companies now manufacture generic versions of ezetimibe [2].
What clinical data supports ezetimibe's effectiveness?
Clinical trials have demonstrated that ezetimibe effectively lowers LDL cholesterol levels when used as monotherapy or in combination with statins. For instance, studies have shown significant reductions in LDL cholesterol compared to placebo [4]. The IMPROVE-IT trial, a large cardiovascular outcomes trial, further established the benefit of adding ezetimibe to statin therapy in patients who had recently experienced an acute coronary syndrome [5].
What is the role of ezetimibe in treating hyperlipidemia?
Ezetimibe is prescribed to treat high cholesterol levels, specifically hyperlipidemia. It is indicated for reducing elevated total cholesterol, LDL cholesterol, and apolipoprotein B (ApoB) in patients with primary hyperlipidemia, either as a monotherapy or in combination with a statin [3]. It is also used for homozygous familial hypercholesterolemia and sitosterolemia [3].
Sources:
[1] https://www.goodrx.com/ezetimibe
[2] https://drugpatentwatch.com/drugs/ezetimibe
[3] https://www.webmd.com/drugs/2/drug-9491/ezetimibe-oral/details
[4] https://www.ahajournals.org/doi/10.1161/CIR.0000000000000313
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1407789